{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:26:15Z","timestamp":1792466775366,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25534222"],"award-info":[{"award-number":["RS-2026-25534222"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2020-NR049583"],"award-info":[{"award-number":["RS-2020-NR049583"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00333784"],"award-info":[{"award-number":["RS-2024-00333784"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119126","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:44:43Z","timestamp":1783467883000},"page":"119126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["SAR-driven optimization of 2-amino-oxazole-based dual CSF-1R\/c-Kit inhibitors for neuroinflammation"],"prefix":"10.1016","volume":"317","author":[{"given":"Hyunah","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungbae","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4294-9909","authenticated-orcid":false,"given":"Hyunmin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujeong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil P.","family":"Bhujbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-4085","authenticated-orcid":false,"given":"Young Hye","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-0405","authenticated-orcid":false,"given":"Jung-Mi","family":"Hah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119126_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0092-8674(85)80047-7","article-title":"The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1","volume":"41","author":"Sherr","year":"1985","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119126_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1128\/jvi.41.2.489-500.1982","article-title":"McDonough feline sarcoma virus: characterization of the molecularly cloned provirus and its feline oncogene (v-CSF-1R)","volume":"41","author":"Donner","year":"1982","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119126_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2141.2003.04108.x","article-title":"Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-CSF-1R, FLT3) in idiopathic myelofibrosis Br","volume":"120","author":"Abu-Duhier","year":"2003","journal-title":"J. Haematol."},{"key":"10.1016\/j.ejmech.2026.119126_bib14","doi-asserted-by":"crossref","first-page":"116253","DOI":"10.1016\/j.ejmech.2024.116253","article-title":"Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R\/c-Kit inhibitors with improved stability and BBB permeability","volume":"268","author":"Baek","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119126_bib4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10787-022-00958-4","article-title":"Colony-stimulating factor 1 receptor signaling in the central nervous system and the potential of its pharmacological inhibitors to halt the progression of neurological disorders","volume":"30","author":"Tarale","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejmech.2026.119126_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119126_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025580","article-title":"The role of atypical protein kinase C in CSF-1-dependent Erk activation and proliferation in myeloid progenitors and macrophages","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119126_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007258","article-title":"(AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119126_bib8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","article-title":"Masitinib is safe and effective for the treatment of canine mast cell tumors","volume":"22","author":"Hahn","year":"2008","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.ejmech.2026.119126_bib9","series-title":"Orphan Designation for Masitinib Mesilate for the Treatment of Amyotrophic Lateral Sclerosis","year":"2018"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119126_bib10","first-page":"587","article-title":"Masitinib for the treatment of mild to moderate Alzheimer's disease Expert rev. Neurotherapeutics","volume":"15","author":"Folch","year":"2015"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119126_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-023-01169-x","article-title":"Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial AB09004 study group","volume":"15","author":"Dubois","year":"2023","journal-title":"Investigators Alzheimers Res. Ther."},{"key":"10.1016\/j.ejmech.2026.119126_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ejmech.2015.08.031","article-title":"Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel CSF-1R kinase inhibitors","volume":"102","author":"Im","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119126_bib13","first-page":"302","article-title":"Elucidation of a novel bioactivation pathway of a 3,4-Unsubstituted isoxazole in human liver microsomes: formation of a glutathione adduct of a cyanoacrolein derivative after isoxazole ring opening drug metabolism and disposition","volume":"39","author":"Yu","year":"2011"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119126_bib15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/ja01448a024","article-title":"The use of oxalyl chloride and bromide for producing acid chlorides, acid bromides or acid anhydrides III","volume":"42","author":"Adams","year":"1920","journal-title":"J. Am. Chem. Soc."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119126_bib16","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1021\/ja00772a052","article-title":"Diphenylphosphoryl azide. A new convenient reagent for a modified curtins reaction and for the peptide synthesism","volume":"94","author":"Shioiri","year":"1972","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119126_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.119126_bib18","first-page":"1039","article-title":"We used reaction biology corp. Kinase HotSpotSM service (www.reactionbiology.com) for determination of IC50 on protein kinases including CSF-1R3 and screening","volume":"vol. 29","year":"2011"},{"key":"10.1016\/j.ejmech.2026.119126_bib20","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bmcl.2010.01.078","article-title":"Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode","volume":"20","author":"Meyers","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119126_bib21","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/1535-7163.MCT-21-0361","article-title":"Vimseltinib: a precision CSF-1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages","volume":"20","author":"Smith","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119126_bib22","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1093\/brain\/awz241","article-title":"CSF-1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice","volume":"142","author":"Mancuso","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2026.119126_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","article-title":"Targeting Fyn kinase in Alzheimer's disease","volume":"83","author":"Nygaard","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2026.119126_bib24","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1172\/JCI85456","article-title":"Activation of tyrosine kinase c-Abl contributes to \u03b1-synuclein-induced neurodegeneration","volume":"126","author":"Brahmachari","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119126_bib25a","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2174\/138920008786485227","article-title":"Artificial membrane assays to assess permeability","volume":"9","author":"Faller","year":"2008","journal-title":"Curr. Drug. Metab."},{"key":"10.1016\/j.ejmech.2026.119126_bib25b","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1087057105281656","article-title":"Rapid Screening of Blood-Brain Barrier Penetration of Drugs Using the Immobilized Artificial Membrane Phosphatidylcholine Column Chromatography","author":"Yoon","year":"2006","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ejmech.2026.119126_bib26","series-title":"Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization","author":"Kerns","year":"2008"},{"key":"10.1016\/j.ejmech.2026.119126_bib27","first-page":"761","article-title":"Determination of the Stability of drugs in Plasma Current protocols in pharmacology","volume":"19","author":"Hartman","year":"2002"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119126_bib28","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1021\/acs.jmedchem.2c01767","article-title":"Chemical optimization of CBL0137 for human African trypanosomiasis lead drug discovery","volume":"66","author":"Singh","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:07:49Z","timestamp":1787040469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"alternative-id":["S0223523426005714"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119126","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SAR-driven optimization of 2-amino-oxazole-based dual CSF-1R\/c-Kit inhibitors for neuroinflammation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119126"}}